Newly diagnosed metastatic ALK+ NSCLC (ECOG 0–2)

Authored by Gilberto Lopes, published on 2026-05-27 23:10:54.0

As of 2025, NCCN and ASCO list alectinib, brigatinib, ensartinib, and lorlatinib as preferred first-line options for metastatic ALK+ NSCLC. ESMO living guidelines similarly support alectinib, brigatinib and lorlatinib (and ensartinib in some regions) as standard first-line ALK TKIs.Global 2025 consensus: Use a next-generation ALK TKI (alectinib, brigatinib, ensartinib, or lorlatinib) in all fit metastatic ALK+ patients, not crizotinib (unless it is the only available option).Main Clinical Trials Lorlatinib – CROWN 5-year data 5-year PFS still not reached, ~60% progression-free at 5 years vs 9.1 months PFS with crizotinib; best intracranial control seen with any TKI. Alectinib – ALEX & long-term follow-up Marked PFS and OS advantage vs crizotinib; mature 5-year OS showing durable benefit and excellent CNS activity. In most recent update PFS with alectinib improved by almost 2 years to 34.8 months with a favorable toxicity profile. Secondary endpoint: final overall survival (OS) analysis showed an encouraging median OS of 81.1 months versus 54.2 months in patients receiving alectinib versus crizotinib (hazard ratio 0.78, 95% confidence interval 0.56-1.08) with almost 50% versus 40% of the patients still alive after 7 years, respectively. Brigatinib & ensartinib – Both improve PFS vs crizotinib and have strong CNS penetration; all four TKIs hold NCCN category 1 preferred status in 2025. (but are less commonly used than alectinib and lorlatinib). Real-world and comparative data (ASCO/ESMO 2025). Large US claims and registry studies suggest broadly comparable OS for frontline alectinib, brigatinib and lorlatinib; all are superior to crizotinib; lorlatinib often shows numerically best CNS outcomes, but CNS AEs are also more pronounced. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

  1. Initial evaluation (all patients)
    Before you decide on systemic therapy: - Confirm diagnosis and stage - Stage IV NSCLC with pathologically confirmed ALK rearrangement (NGS or validated ALK test, FISH, IHC). Exclude potentially curable oligometastatic scenarios where upfront local therapy would change intent. Baseline work-up - ECOG PS, comorbidities, age, cardiovascular and neurocognitive status. - Brain MRI for all (CNS risk is central to the algorithm). - Comprehensive labs including fasting lipid panel, glucose/HbA1c, LFTs, renal function. - Check drug access / reimbursement
    • If stable/asymptomatic CNS disease or no brain mets
      • Higher comorbidity / toxicity concern → 1L alectinib or brigatinib (± ensartinib where standard)
      • Low co-morbidity / high CNS-risk / young → 1L lorlatinib
        • Oligoprogression
          • local therapy + continue lorlatinib
            • Later-line options (after ≥1 ALK TKI + chemotherapy)
              Clinical trial (4th-gen ALK TKIs, bispecifics, ADCs). Platinum-pemetrexed re-challenge in select patients with long prior benefit. Off-label targeted therapy for specific off-target drivers (e.g., MET, BRAF, KRAS) if discovered on re-biopsy. Palliative RT for symptom control; best supportive care when appropriate.
        • Systemic progression
          • platinum-pemetrexed (± bevacizumab)
            Strongly consider clinical trial with 4th-gen ALK TKI.
            • Later-line options (after ≥1 ALK TKI + chemotherapy)
              Clinical trial (4th-gen ALK TKIs, bispecifics, ADCs). Platinum-pemetrexed re-challenge in select patients with long prior benefit. Off-label targeted therapy for specific off-target drivers (e.g., MET, BRAF, KRAS) if discovered on re-biopsy. Palliative RT for symptom control; best supportive care when appropriate.
    • If symptomatic CNS disease
      • Local CNS therapy
        • Start CNS-active ALK TKI
          ALK TKI (alectinib / brigatinib / ensartinib)
          • Systemic progression on 2G ALK TKI
            • Switch to lorlatinib (if available) ± re-biopsy
              • Later-line options (after ≥1 ALK TKI + chemotherapy)
                Clinical trial (4th-gen ALK TKIs, bispecifics, ADCs). Platinum-pemetrexed re-challenge in select patients with long prior benefit. Off-label targeted therapy for specific off-target drivers (e.g., MET, BRAF, KRAS) if discovered on re-biopsy. Palliative RT for symptom control; best supportive care when appropriate.
          • Oligoprogression on 2G ALK TKI
            • local ablative therapy + continue same TKI
              • Later-line options (after ≥1 ALK TKI + chemotherapy)
                Clinical trial (4th-gen ALK TKIs, bispecifics, ADCs). Platinum-pemetrexed re-challenge in select patients with long prior benefit. Off-label targeted therapy for specific off-target drivers (e.g., MET, BRAF, KRAS) if discovered on re-biopsy. Palliative RT for symptom control; best supportive care when appropriate.
  2. Throughout
    - Re-image brain periodically, more often in those not on lorlatinib. - Manage long-term toxicities (lipids, mood, cognition, myalgias, liver enzymes) proactively. - Prioritize trial enrollment where possible, especially post-lorlatinib.
  3. Notes on Immunotherapy
    Single-agent anti-PD-1/PD-L1 has poor activity in ALK-rearranged NSCLC; objective response rates are low and PFS short. Chemo-IO combinations may be considered, but evidence in ALK+ is weak; prioritize chemotherapy ± VEGF inhibition and trials.
  4. Clinical trial strongly recommended
    4th-generation ALK TKIs (e.g., NVL-655) showing promising early activity in patients who have exhausted prior TKIs including lorlatinib. Access programs and clinical trials are available in several countries
tosprivacyAlectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerA Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung CancerEnsartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialPhase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse